摘要
目的观察表皮生长因子受体酪氨酸激酶抑制剂吉非替尼单药治疗老年晚期非小细胞肺癌的疗效和毒副作用。方法2003年9月至2006年11月期间，57例65岁以上老年晚期非小细胞肺癌患者，单药口服吉非替尼250mg 1次／d。应用方差分析、t检验、Kaplan-Meier进行统计分析。结果男31例，女26例；年龄65～86岁，中位年龄71岁；Ⅲ期10例，Ⅳ期47例。近期疗效：完全缓解（CR）1例（1．8％），部分缓解（PR）14例（25．5％），有效率（CR＋PR）27．3％；疾病稳定（SD）24例（43．6％），疾病控制率（CR＋PR＋SD）70．9％；疾病进展16例（29．1％）；症状改善率63．6％，症状改善中位时间为8d（3-17d），症状改善持续中位时间为5．8个月；中位疾病进展时间5．3个月（27d至24个月），中位生存期7．8个月（18d至34个月），1年生存率33％。主要不良反应为皮疹42．1％、腹泻31．6％，大部分腹泻患者为轻度，经对症处理后可缓解，仅1例患者因腹泻停药。皮肤瘙痒4例（7．3％），皮肤干燥4例（7．3％），口腔疼痛伴溃疡1例（1．8％），还有1例（1．8％）患者因出现双足皮肤干燥、脱皮和趾甲皲裂而影响行走。结论吉非替尼单药治疗老年晚期非小细胞肺癌疗效肯定，毒副作用相对较小，患者耐受性好。
Objective To investigate the efficacy and toxicity of gefitinib, an epidermal growth factor receptortyrosine kinase inhibitor, in the treatment of the elderly with advanced non-small-cell lung cancer （NSCLC）. Methods From Sep. 2003 to Nov. 2006, 57 old patients with stage-Ⅲ or -Ⅳ NSCLC were enrolled. Gefitinib was administered orally 250mg daily. Clinical data were analysed using chi-square test, t-test and Kaplan-Meier survival analysis. Results All 57 patients （males/females, 31/26; median age, 71 years; stage-Ⅲ/stage-Ⅳ, 10/47） were analyzed. Complete response （CR） rate and partial response （PR） rate were 1.8% and 25.5 %, respectively; effective rate （CR＋PR） was 27.3% ; stability of disease （SD） was 43.6% ; disease control rate was 70.9% ; progression of disease （PD） was 29.1% ; the rate of symptom relief was 63.6% and median time to occurrence of symptom improvement was 8 d and duration of symptom improvement was 5.8 months. Median time to progression （TTP） and median time of survival was 5.3 months and 7.8 months, respectively. One-year survival rate was 33%. The major adverse events were mild skin rash （42.1%） and diarrhea （31.6%）. Only one case quitted the treatment because of severe diarrhea. Conclusion Monotherapy with gefitinib is effective and tolerable for the elderly with advanced NSCLC.
出处
《中华老年多器官疾病杂志》
2008年第1期40-42,46,共4页
Chinese Journal of Multiple Organ Diseases in the Elderly
关键词
癌
非小细胞肺
吉非替尼
靶向治疗
cancer, non-small cell lung
gefitinib
targeting therapy
